Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Published in: Journal of Inherited Metabolic Disease 3/2016

Open Access 01-05-2016 | Original Article

Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB

Authors: O. L. M. Meijer, L. Welling, M. J. Valstar, L. H. Hoefsloot, H. T. Brüggenwirth, A. T. van der Ploeg, G. J. G. Ruijter, T. Wagemans, F. A. Wijburg, N. van Vlies

Published in: Journal of Inherited Metabolic Disease | Issue 3/2016

Login to get access

Abstract

Background

Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare genetic disorder in which the deficiency of the lysosomal enzyme N-acetyl-α-glucosaminidase (NAGLU) results in the accumulation of heparan sulfate (HS), leading to progressive neurocognitive deterioration. In MPS IIIB a wide spectrum of disease severity is seen. Due to a large allelic heterogeneity, establishing genotype-phenotype correlations is difficult. However, reliable prediction of the natural course of the disease is needed, in particular for the assessment of the efficacy of potential therapies.

Methods

To identify markers that correlate with disease severity, all Dutch patients diagnosed with MPS IIIB were characterised as either rapid (RP; classical, severe phenotype) or slow progressors (SP; non-classical, less severe phenotype), based on clinical data. NAGLU activity and HS levels were measured in patients’ fibroblasts after culturing at different temperatures.

Results

A small, though significant difference in NAGLU activity was measured between RP and SP patients after culturing at 37 °C (p < 0.01). Culturing at 30 °C resulted in more pronounced and significantly higher NAGLU activity levels in SP patients (p < 0.001) with a NAGLU activity of 0.58 nmol.mg-1.hr-1 calculated to be the optimal cut-off value to distinguish between the groups (sensitivity and specificity 100 %). A lower capacity of patients’ fibroblasts to increase NAGLU activity at 30 °C could significantly predict for the loss of several disease specific functions.

Conclusion

NAGLU activity in fibroblasts cultured at 30 °C can be used to discriminate between RP and SP MPS IIIB patients and the capacity of cells to increase NAGLU activity at lower temperatures correlates with disease symptoms.
Literature
Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017CrossRefPubMed
Beesley CE, Young EP, Vellodi A, Winchester BG (1998) Identification of 12 novel mutations in the α-N-acetylglucosaminidase gene in 14 patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 35:910–914CrossRefPubMedPubMedCentral
Beesley C, Moraitou M, Winchester B et al (2004) Sanfilippo B syndrome: Molecular defects in Greek patients. Clin Genet 65:143–149CrossRefPubMed
Beesley CE, Jackson M, Young EP et al (2005) Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB). J Inherit Metab Dis 28:759–767CrossRefPubMed
Bunge S, Knigge A, Steglich C et al (1999) Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel α-N-acetylglucosaminidase gene mutations. J Med Genet 36:28–31PubMedPubMedCentral
Champion KJ, Basehore MJ, Wood T et al (2010) Identification and characterization of a novel homozygous deletion in the α-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB). Mol Genet Metab 100:51–56CrossRefPubMed
Chinen Y, Tohma T, Izumikawa Y et al (2005) Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the α-N-acetylglucosaminidase gene from the Okinawa islands in Japan. J Hum Genet 50:357–359CrossRefPubMed
Emre S, Terzioglu M, Tokatli A et al (2002) Sanfilippo syndrome in Turkey: identification of novel mutations in subtypes A and B. Hum Mutat 19:184–185
Esko JD, Kimata K, Lindahl U (2009) Chapter 16 Proteoglycans and Sulfated Glycosaminoglycans. In: Varki A, Cummings RD, Esko JD (eds) Essentials of glycobiology, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY)
Esposito S, Balzano N, Daniele A et al (2000) Heparan N-sulfatase gene: two novel mutations and transient expression of 15 defects. Biochim Biophys Acta 1501:1–11
Gootjes J, Schmohl F, Mooijer PA et al (2004) Identification of the molecular defect in patients with peroxisomal mosaicism using a novel method involving culturing of cells at 40°C: implications for other inborn errors of metabolism. Hum Mutat 24:130–139
Houten SM, Frenkel J, Rijkers GT et al (2002) Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 11:3115–3124CrossRefPubMed
Kingma SDK, Langereis EJ, de Klerk CM et al (2013) An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life. Orphanet J Rare Dis 8:99CrossRefPubMedPubMedCentral
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMed
Malinowska M, Wilkinson FL, Bennett W et al (2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98:235–242CrossRefPubMed
Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5, e14192CrossRefPubMedPubMedCentral
Marsh J, Fensom AH (1985) 4-Methylumbelliferyl α-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clin Genet 27:258–262CrossRefPubMed
Meijer OL, van Vlies N, Wijburg FA (2013) Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome). Expert Opin Orphan Drugs 1:717–730
Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM et al (2007) Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C: Semin Med Genet 145C:293–301CrossRef
Ouesleti S, Brunel V, Ben TH et al (2011) Molecular characterization of MPS IIIA, MPS IIIB and MPS IIIC in Tunisian patients. Clin Chim Acta 412:2326–2331CrossRefPubMed
Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156CrossRefPubMed
Selmer KK, Gilfillan GD, Strømme P et al (2012) A mild form of Mucopolysaccharidosis IIIB diagnosed with targeted next-generation sequencing of linked genomic regions. Eur J Hum Genet 20:58–63CrossRefPubMed
Tang J, Pan J, Guo Y et al (2013) Mucopolysaccharidosis type IIIB mutations in Chinese patients: identification of two novel NAGLU mutations and analysis of two cases involving prenatal diagnosis. Clin Chim Acta 419:33–38
Tessitore A, Villani GR, Di Domenico C et al (2000) Molecular defects in the α-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Hum Genet 107:568–576CrossRefPubMed
Valstar MJ, Ruijter GJ, Van Diggelen OP et al (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252
Valstar MJ, Bruggenwirth HT, Olmer R et al (2010a) Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype. J Inherit Metab Dis 33:759–767CrossRefPubMedPubMedCentral
Valstar MJ, Neijs S, Bruggenwirth HT et al (2010b) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887CrossRefPubMed
Van de Kamp JJ, van Pelt JF, Liem KO et al (1976) Clinical variability in Sanfilippo B disease: a report on six patients in two related sibships. Clin Genet 10:279–284CrossRefPubMed
Weber B, Guo XH, Kleijer WJ et al (1999) Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet 7:34–44CrossRefPubMed
Metadata
Title
Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB
Authors
O. L. M. Meijer
L. Welling
M. J. Valstar
L. H. Hoefsloot
H. T. Brüggenwirth
A. T. van der Ploeg
G. J. G. Ruijter
T. Wagemans
F. A. Wijburg
N. van Vlies
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 3/2016
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9916-2

Other articles of this Issue 3/2016

Journal of Inherited Metabolic Disease 3/2016 Go to the issue

original article

Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD)

Editorial

Recommendations and guidelines in the JIMD: suggested procedures and avoidance of conflicts of interest

Original Article

Clinical phenotype, biochemical profile, and treatment in 19 patients with arginase 1 deficiency

Original Article

Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice

Original Article

Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study

Original Article

Altered mTOR signalling in nephropathic cystinosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits